<DOC>
	<DOCNO>NCT00002986</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness topotecan plus carmustine patient recurrent primary malignant glioma .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose topotecan administer combination fix dose carmustine . - Determine toxic effect topotecan carmustine patient recurrent primary malignant glioma . OUTLINE : Topotecan administer ambulatory infusion pump 72 hour week . Topotecan dose escalation carry cohort three patient . Dose escalation continue toxic effect disease progression observe patient . Carmustine administer 1 hour every 6 week , day first topotecan dose week . Three patient treat initial dose level topotecan , one patient experience dose limit toxicity ( DLT ) , additional 3 patient must treat dose level without DLT order dose escalation proceed . The MTD high dose DLT occur 1 6 patient . Patients evaluate every 6 week cycle . PROJECTED ACCRUAL : An estimated 18-36 patient enter .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent primary malignant glioma Measurable recurrent residual primary central nervous system neoplasm confirm MRI PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky least 60 % Hematopoietic : Hematocrit great 29 % ANC great 1,500/mm^3 Platelet count great 125,000/mm^3 Hepatic : SGOT le 1.5 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal : Creatinine le 1.5 mg/dL BUN le 25 mg/dL Other : Not pregnant Effective contraceptive method must use duration study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy within 6 week study No prior topotecan carmustine treatment failure No 1 prior chemotherapy regimen Endocrine therapy : Patients take corticosteroid must stable dose least 2 week prior study dose escalate entry level Radiotherapy : No prior radiotherapy within 6 week study Surgery : No prior surgical resection within 3 week study Other : No concurrent medication may interfere study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>